Yeshaya Fishman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yeshaya Fishman has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Bodzin
Department of Biology, Yeshiva College, Yeshiva University, 500 W 185th Str., New York, NY 10033, USA
1 shared publication - Brian Lerman
Department of Biology, Yeshiva College, Yeshiva University, 500 W 185th Str., New York, NY 10033, USA
1 shared publication - Radhashree Maitra
Department of Biology, Yeshiva University, New York, NY, United States
1 shared publication - Tzuriel Sapir
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
1 shared publication - Zaelig Averch
Department of Biology, Yeshiva College, Yeshiva University, 500 W 185th Str., New York, NY 10033, USA
1 shared publication
Latest Publications
- Open Access
- 3 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8606
COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a viral agent that causes Coronavirus disease 2019 (COVID-19), a disease that causes flu-like symptoms that, when exacerbated, can have life-threatening consequences. COVID-19 has been linked to persistent symptoms, sequelae, and medical complications that can last months after the initial infection. This systematic review aims to elucidate the innate and adaptive immune mechanisms involved and identify potential characteristics of COVID-19 pathology that may increase symptom duration. We also describe he three different stages of COVID-19—viral replication, immune hyperactivation, and post-acute sequelae—as well as each phase’s corresponding immune response. Finally, we use this multiphasic approach to describe different treatment approaches for each of the three stages—antivirals, immunosuppressants and monoclonal antibodies, and continued immunosuppressants—to fully curate the treatment to the stage of disease.
- 3 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8606
Open AccessCOVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a viral agent that causes Coronavirus disease 2019 (COVID-19), a disease that causes flu-like symptoms that, when exacerbated, can have life-threatening consequences. COVID-19 has been linked to persistent symptoms, sequelae, and medical complications that can last months after the initial infection. This systematic review aims to elucidate the innate and adaptive immune mechanisms involved and identify potential characteristics of COVID-19 pathology that may increase symptom duration. We also describe he three different stages of COVID-19—viral replication, immune hyperactivation, and post-acute sequelae—as well as each phase’s corresponding immune response. Finally, we use this multiphasic approach to describe different treatment approaches for each of the three stages—antivirals, immunosuppressants and monoclonal antibodies, and continued immunosuppressants—to fully curate the treatment to the stage of disease.